Haemonetics Net Income
| HAE Stock | USD 57.78 0.02 0.03% |
As of the 16th of February 2026, Haemonetics retains the Risk Adjusted Performance of (0.10), standard deviation of 2.1, and Market Risk Adjusted Performance of (2.10). Haemonetics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Haemonetics standard deviation, maximum drawdown, kurtosis, as well as the relationship between the information ratio and potential upside to decide if Haemonetics is priced fairly, providing market reflects its last-minute price of 57.78 per share. Given that Haemonetics has information ratio of (0.17), we strongly advise you to confirm Haemonetics's regular market performance to make sure the company can sustain itself at a future point.
Haemonetics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 2.6895 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 192.8 M | 202.5 M | |
| Net Income Applicable To Common Shares | 192.8 M | 202.5 M | |
| Net Income From Continuing Ops | 192.8 M | 202.5 M | |
| Net Income Per Share | 2.32 | 2.43 | |
| Net Income Per E B T | 0.77 | 0.44 |
Haemonetics | Net Income | Build AI portfolio with Haemonetics Stock |
Analyzing Haemonetics's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Haemonetics's current valuation and future prospects.
Latest Haemonetics' Net Income Growth Pattern
Below is the plot of the Net Income of Haemonetics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Haemonetics financial statement analysis. It represents the amount of money remaining after all of Haemonetics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Haemonetics' Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Haemonetics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 167.68 M | 10 Years Trend |
|
Net Income |
| Timeline |
Haemonetics Net Income Regression Statistics
| Arithmetic Mean | 69,737,955 | |
| Geometric Mean | 60,267,011 | |
| Coefficient Of Variation | 102.27 | |
| Mean Deviation | 54,561,242 | |
| Median | 55,019,000 | |
| Standard Deviation | 71,320,476 | |
| Sample Variance | 5086.6T | |
| Range | 258.1M | |
| R-Value | 0.78 | |
| Mean Square Error | 2102.5T | |
| R-Squared | 0.61 | |
| Significance | 0.0002 | |
| Slope | 11,053,299 | |
| Total Sum of Squares | 81385.8T |
Haemonetics Net Income History
Other Fundumenentals of Haemonetics
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Haemonetics Net Income component correlations
Haemonetics Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Haemonetics is extremely important. It helps to project a fair market value of Haemonetics Stock properly, considering its historical fundamentals such as Net Income. Since Haemonetics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Haemonetics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Haemonetics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Health Care Equipment & Supplies sector continue expanding? Could Haemonetics diversify its offerings? Factors like these will boost the valuation of Haemonetics. Market participants price Haemonetics higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Haemonetics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.284 | Earnings Share 3.63 | Revenue Per Share | Quarterly Revenue Growth (0.03) | Return On Assets |
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Haemonetics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Haemonetics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Haemonetics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Haemonetics.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Haemonetics on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Haemonetics or generate 0.0% return on investment in Haemonetics over 90 days. Haemonetics is related to or competes with Allurion Technologies, Aethlon Medical, Co Diagnostics, Vivos Therapeutics, Ekso Bionics, Adagio Medical, and Aytu BioScience. Haemonetics Corporation, a healthcare company, provides medical products and solutions More
Haemonetics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Haemonetics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Haemonetics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.17) | |||
| Maximum Drawdown | 13.62 | |||
| Value At Risk | (3.70) | |||
| Potential Upside | 2.66 |
Haemonetics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Haemonetics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Haemonetics' standard deviation. In reality, there are many statistical measures that can use Haemonetics historical prices to predict the future Haemonetics' volatility.| Risk Adjusted Performance | (0.10) | |||
| Jensen Alpha | (0.30) | |||
| Total Risk Alpha | (0.45) | |||
| Treynor Ratio | (2.11) |
Haemonetics February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.10) | |||
| Market Risk Adjusted Performance | (2.10) | |||
| Mean Deviation | 1.49 | |||
| Coefficient Of Variation | (754.08) | |||
| Standard Deviation | 2.1 | |||
| Variance | 4.42 | |||
| Information Ratio | (0.17) | |||
| Jensen Alpha | (0.30) | |||
| Total Risk Alpha | (0.45) | |||
| Treynor Ratio | (2.11) | |||
| Maximum Drawdown | 13.62 | |||
| Value At Risk | (3.70) | |||
| Potential Upside | 2.66 | |||
| Skewness | (0.98) | |||
| Kurtosis | 3.42 |
Haemonetics Backtested Returns
Haemonetics holds Efficiency (Sharpe) Ratio of -0.18, which attests that the entity had a -0.18 % return per unit of risk over the last 3 months. Haemonetics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Haemonetics' Market Risk Adjusted Performance of (2.10), standard deviation of 2.1, and Risk Adjusted Performance of (0.10) to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 0.14, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Haemonetics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Haemonetics is expected to be smaller as well. At this point, Haemonetics has a negative expected return of -0.38%. Please make sure to check out Haemonetics' standard deviation, maximum drawdown, kurtosis, as well as the relationship between the total risk alpha and potential upside , to decide if Haemonetics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.31 |
Poor reverse predictability
Haemonetics has poor reverse predictability. Overlapping area represents the amount of predictability between Haemonetics time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Haemonetics price movement. The serial correlation of -0.31 indicates that nearly 31.0% of current Haemonetics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.31 | |
| Spearman Rank Test | -0.07 | |
| Residual Average | 0.0 | |
| Price Variance | 75.38 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Haemonetics Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Haemonetics reported net income of 167.68 M. This is 50.87% lower than that of the Health Care Equipment & Supplies sector and 68.29% higher than that of the Health Care industry. The net income for all United States stocks is 70.63% higher than that of the company.
Haemonetics Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Haemonetics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Haemonetics could also be used in its relative valuation, which is a method of valuing Haemonetics by comparing valuation metrics of similar companies.Haemonetics is currently under evaluation in net income category among its peers.
Haemonetics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Haemonetics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Haemonetics' managers, analysts, and investors.Environmental | Governance | Social |
Haemonetics Institutional Holders
Institutional Holdings refers to the ownership stake in Haemonetics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Haemonetics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Haemonetics' value.| Shares | Btim Corp | 2025-06-30 | 1.1 M | Dimensional Fund Advisors, Inc. | 2025-06-30 | 1.1 M | Allspring Global Investments Holdings, Llc | 2025-06-30 | 949.5 K | Sg Capital Management, Llc | 2025-06-30 | 906.9 K | Schroder Investment Management Group | 2025-06-30 | 892.4 K | Ubs Group Ag | 2025-06-30 | 869.8 K | Fmr Inc | 2025-06-30 | 835.8 K | Victory Capital Management Inc. | 2025-06-30 | 778.8 K | Fisher Asset Management, Llc | 2025-06-30 | 689.1 K | Blackrock Inc | 2025-06-30 | 6.4 M | Vanguard Group Inc | 2025-06-30 | 5 M |
Haemonetics Fundamentals
| Return On Equity | 0.19 | ||||
| Return On Asset | 0.0645 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.21 % | ||||
| Current Valuation | 3.55 B | ||||
| Shares Outstanding | 46.47 M | ||||
| Shares Owned By Insiders | 1.19 % | ||||
| Shares Owned By Institutions | 98.81 % | ||||
| Number Of Shares Shorted | 2.41 M | ||||
| Price To Earning | 50.35 X | ||||
| Price To Book | 2.94 X | ||||
| Price To Sales | 2.05 X | ||||
| Revenue | 1.36 B | ||||
| Gross Profit | 793.78 M | ||||
| EBITDA | 355.99 M | ||||
| Net Income | 167.68 M | ||||
| Cash And Equivalents | 306.76 M | ||||
| Cash Per Share | 4.79 X | ||||
| Total Debt | 1.22 B | ||||
| Debt To Equity | 1.12 % | ||||
| Current Ratio | 2.73 X | ||||
| Book Value Per Share | 19.46 X | ||||
| Cash Flow From Operations | 181.72 M | ||||
| Short Ratio | 3.08 X | ||||
| Earnings Per Share | 3.63 X | ||||
| Price To Earnings To Growth | 0.88 X | ||||
| Target Price | 88.0 | ||||
| Number Of Employees | 3.02 K | ||||
| Beta | 0.27 | ||||
| Market Capitalization | 2.7 B | ||||
| Total Asset | 2.45 B | ||||
| Retained Earnings | 352.17 M | ||||
| Working Capital | 356.86 M | ||||
| Current Asset | 488.09 M | ||||
| Current Liabilities | 185.55 M | ||||
| Net Asset | 2.45 B |
About Haemonetics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Haemonetics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Haemonetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Haemonetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports:Check out For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Will Health Care Equipment & Supplies sector continue expanding? Could Haemonetics diversify its offerings? Factors like these will boost the valuation of Haemonetics. Market participants price Haemonetics higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Haemonetics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.284 | Earnings Share 3.63 | Revenue Per Share | Quarterly Revenue Growth (0.03) | Return On Assets |
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Haemonetics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.